Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received equity awards on August 14, 2026. She was granted 254,800 shares of Common Stock in the form of restricted stock units, which begin vesting on April 14, 2027 and continue in quarterly installments, subject to continued service. She was also granted two employee stock option awards covering 137,200 shares and 250,000 shares of Common Stock at an exercise price of $5.84 per share, each vesting over four years under specified monthly schedules. Following the RSU grant, she directly owned 493,705 Common shares.
ImageneBio, Inc. reported equity compensation awards to its Chief Financial Officer, Yanina Grant-Huerta. On August 14, 2026 she received a grant of 56,000 stock options with an exercise price of $5.84 per share, expiring on August 13, 2036. She also received a total of 104,000 restricted stock units, represented by two grants of 65,000 and 39,000 shares of common stock underlying RSUs. Footnotes state these updated awards replace a previously described but not yet granted package, and that 25% of both the RSUs and options vest on July 20, 2027 with the remainder vesting in equal periodic installments thereafter, subject to continued service.
ImageneBio, Inc. is reported to have a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert. As of the close of business on June 30, 2026, these reporting persons collectively may be deemed to beneficially own 1,128,647 shares of ImageneBio common stock, or approximately 9.99% of the outstanding shares, including shares held in a managed account.
The group also holds pre-funded warrants exercisable for an aggregate of 528,947 shares at an exercise price of $0.001 per share. These warrants are exercisable at any time and do not expire, but a 9.99% beneficial ownership blocker currently limits exercise to 18,645 of those shares. The ownership percentages are based on 11,279,130 shares outstanding as of June 30, 2026, plus the exercisable warrant shares.
ImageneBio, Inc. has filed a shelf registration that permits it to offer and sell up to $200,000,000 of common stock, preferred stock, debt securities and warrants over time. Within this shelf, the company has also put in place an at‑the‑market program to sell up to $17,000,000 of common stock through Jefferies LLC as sales agent. The company is a clinical‑stage biopharmaceutical developer focused on immunological, autoimmune and inflammatory diseases, led by its anti‑OX40 antibody olevaprubart (IMG‑007). Net proceeds from any sales will be used for general corporate purposes, including clinical trial and other R&D spending, working capital and administrative expenses.
ImageneBio, Inc. is filing Post-Effective Amendment No. 2 to convert its existing Form S-1 into a Form S-3 shelf registration for the resale of 1,371,224 shares of common stock. These shares were issued in a July 25, 2025 PIPE Financing under a Subscription Agreement with certain investors and are being registered to satisfy granted registration rights.
The shares may be sold from time to time by the selling stockholders through various methods and at varying prices. ImageneBio will not receive any proceeds from these sales and will instead bear the registration expenses. The common stock trades on Nasdaq under the symbol IMA, and the last quoted sale price was $5.71 on August 4, 2026. As of July 15, 2026, there were 11,279,130 shares outstanding. The company is an emerging growth company and smaller reporting company, allowing use of scaled disclosure and extended adoption periods for certain accounting standards.
ImageneBio, Inc. provides an updated prospectus supplement for the resale of up to 2,508,337 shares of common stock under its Form S-1 registration statement (No. 333-290108). The shares may be offered and sold from time to time by identified selling stockholders.
The supplement incorporates information from ImageneBio’s Quarterly Report on Form 10-Q filed on August 5, 2026, which is attached in relevant part. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMA, and the last reported sale price was $5.71 per share on August 4, 2026.
The document emphasizes that investing in these securities involves a high degree of risk and directs readers to the “Risk Factors” section in the base prospectus and any amendments or supplements.
ImageneBio, Inc. is registering for resale up to 5,770,335 shares of common stock on behalf of selling stockholders. These shares are issuable upon exercise of pre-funded warrants that were sold in an April 14, 2026 private placement for an aggregate purchase price of approximately $30.0 million at $5.199 per warrant with a $0.001 per share exercise price. The company will not receive proceeds from any resale of the shares, and will receive only the nominal exercise price if warrants are exercised for cash. As of July 15, 2026, 11,279,130 shares of common stock were outstanding. The pre-funded warrants are exercisable at any time, do not expire until exercised in full, and are subject to a beneficial ownership limitation not to exceed 19.99%. ImageneBio’s common stock trades on the Nasdaq Capital Market under the symbol IMA.